Yiannis Koullias

Yiannis Koullias

Auto-generated profile, based on publicly available information

Yiannis Koullias

Gilead Sciences, Inc., Foster City, CA, 94404, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ASAnca Streinu-Cercel
Anca Streinu-Cercel
ACAntonella Castagna
Antonella Castagna
SCShan-Chwen Chang
Shan-Chwen Chang
YCYao-Shen Chen
Yao-Shen Chen
YKYiannis Koullias
Yiannis Koullias
JCJuan González del Castillo
Juan González del Castillo
Background: Obeldesivir is an oral nucleoside analog prodrug inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: Nonhospitalized adults with risk factors for developing severe coronavirus disease 2019 (COVID-19) were enrolled ≤5 days from COVID-19 symptom onset and randomized 1:1 to receive obeldesivir 350 mg or placebo twice daily for 5 days. The primary end point was COVID-19–related hospitalization or all-cause death by day 29. Other end points included time to symptom alleviation by day 15, change in SARS-CoV-2 viral RNA copy number and infectious viral titer, and incidence of adverse events and laboratory abnormalities. Results: Four hundred and sixty five participants were randomized and received ≥1 dose of study drug. Baseline characteristics were generally balanced between groups. Overall, 58% had received ≥1 COVID-19 vaccination, and 92% were seropositive for SARS-CoV-2 antibodies. COVID-19–related hospitalization or all-cause death by day 29 was reported in 0 of 211 (0%) participants with obeldesivir and 1 of 207 (0.5%) participants with placebo (log-rank P = .32). Time to COVID-19 symptom alleviation was numerically shorter with obeldesivir versus placebo. Obeldesivir reduced viral RNA copy number at day 5 and infectious titer at days 3 and 5 versus placebo. The safety profile was generally comparable across arms. Conclusions: Although underpowered in the context of a changing COVID-19 landscape, obeldesivir in nonhospitalized adults with targeted risk factors did not improve COVID-19–related hospitalization or all-cause death. Obeldesivir reduced viral RNA copy number and infectious titer, demonstrating its ability to inhibit SARS-CoV-2 replication, and resulted in numerically faster symptom alleviation. Clinical Trials Registration: NCT05603143; EudraCT 2022-002741-18.

31 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CPChi‐Chi Peng
Chi‐Chi Peng
RHRita Humeniuk
Rita Humeniuk
ARAnuja Raut
Anuja Raut
AKAnna Kwan
Anna Kwan
LMLily Mak
Lily Mak
LCLuzelena Caro
Luzelena Caro

19 January 2026 in Antiviral Research
Verified
Journal Article
Closed access
CHCharlotte Hedskog
Charlotte Hedskog
LRLauren Rodriguez
Lauren Rodriguez
YHYu Hu
Yu Hu
JLJiani Li
Jiani Li
DHDong Han
Dong Han
RHRobert H. Hyland
Robert H. Hyland

22 May 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
Sophia KooSophia Koo
Sophia Koo
TBTyler D. Bold
Tyler D. Bold
MCMatthew Pellan Cheng
Matthew Pellan Cheng
DFDimitrios Farmakiotis
Dimitrios Farmakiotis
JHJoshua aiden Hill
Joshua aiden Hill
SHSarah P. Hammond
Sarah P. Hammond

5 August 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
LRLauren Rodriguez
Lauren Rodriguez
KAKristen Andreatta
Kristen Andreatta
SCShuguang Chen
Shuguang Chen
YHYu Hu
Yu Hu
JLJiani Li
Jiani Li
CHCharlotte Hedskog
Charlotte Hedskog
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo ( P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P < 0.05). Mathematical modeling of viral load kinetics in participants with kidney transplants predicted a >13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04745351 ; EudraCT registration no. 2020-005416-22.